Minimal Residual Disease

About a fifth of children initially cured of acute lymphoblastic leukaemia (ALL), later suffer a relapse due to the persistence of small numbers of cancer cells throughout treatment (‘minimal residual disease’ or MRD). Our research focuses on seeing MRD testing become part of the routine clinical management of all children with ALL

Group Leader Name
Dr Rosemary Sutton
Rosemary Sutton
Research Area

Back to top